Liquid Biopsy for Detection of Pancreaticobiliary Cancers by Functional Enrichment and Immunofluorescent Profiling of Circulating Tumor Cells and Their Clusters

Circulating tumor cells (CTCs) have historically been used for prognostication in oncology. We evaluate the performance of liquid biopsy CTC assay as a diagnostic tool in suspected pancreaticobiliary cancers (PBC). The assay utilizes functional enrichment of CTCs followed by immunofluorescent profil...

Full description

Saved in:
Bibliographic Details
Published in:Cancers 2024-04, Vol.16 (7), p.1400
Main Authors: Gaya, Andrew, Rohatgi, Nitesh, Limaye, Sewanti, Shreenivas, Aditya, Ajami, Ramin, Akolkar, Dadasaheb, Datta, Vineet, Srinivasan, Ajay, Patil, Darshana
Format: Article
Language:English
Subjects:
Abdomen
Antigens
Asymptomatic
Bile ducts
Biopsy
Blood
Cancer
CD45 antigen
Diagnosis
Endoscopy
Ethylenediaminetetraacetic acid
Medical examination
Medical prognosis
Metastasis
Observational studies
Pancreatic cancer
Patients
Sampling
Tumor cells
Tumors
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Circulating tumor cells (CTCs) have historically been used for prognostication in oncology. We evaluate the performance of liquid biopsy CTC assay as a diagnostic tool in suspected pancreaticobiliary cancers (PBC). The assay utilizes functional enrichment of CTCs followed by immunofluorescent profiling of organ-specific markers. The performance of the assay was first evaluated in a multicentric case-control study of blood samples from 360 participants, including 188 PBC cases (pre-biopsy samples) and 172 healthy individuals. A subsequent prospective observational study included pre-biopsy blood samples from 88 individuals with suspicion of PBC and no prior diagnosis of cancer. CTCs were harvested using a unique functional enrichment method and used for immunofluorescent profiling for CA19.9, Maspin, EpCAM, CK, and CD45, blinded to the tissue histopathological diagnosis. TruBlood malignant or non-malignant predictions were compared with tissue diagnoses to establish sensitivity and specificity. The test had 95.9% overall sensitivity (95% CI: 86.0-99.5%) and 92.3% specificity (95% CI: 79.13% to 98.38%) to differentiate PBC (n = 49) from benign conditions (n = 39). The high accuracy of the CTC-based TruBlood test demonstrates its potential clinical application as a diagnostic tool to assist the effective detection of PBC when tissue sampling is unviable or inconclusive.
ISSN:2072-6694
2072-6694
DOI:10.3390/cancers16071400